Turnstone Biologics Reports Initial Data From Phase 1 Trial Of TIDAL-01 In Metastatic Colorectal Cancer; Overall Response Rate Of 25% And 50% Disease Control Rate Observed In First 4 Evaluable Patients

Author: Benzinga Newsdesk | August 14, 2024 04:12pm

• Overall response rate ("ORR") of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC
• Complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year
• Favorable tolerability profile and demonstrated manufacturing success
• Product characterization and translational data support biological hypothesis for Selected TILs

SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer ("MSS mCRC").

Posted In: TSBX